M162 M162 (Didanosine delayed release 400 mg)
Pill imprint M162 M162 has been identified as Didanosine delayed release 400 mg.
Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 400 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for M162 M162 (Didanosine delayed release 400 mg)
- 400 mg
- White & Yellow
- Prescription only
- Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- N - Not a controlled drug
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- ferrosoferric oxide
methacrylic acid - methyl methacrylate copolymer (1:1)
ferric oxide red
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
ferric oxide yellow
Didanosine delayed release is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...